Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. Vertex is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad clinical pipeline in kidney disease, neuropathic pain, type 1 diabetes and myotonic dystrophy type 1. Its SEC filings give investors and analysts detailed insight into financial performance, risk factors and material events affecting the business.
Recent Form 8-K filings from Vertex have reported quarterly financial results and related guidance under Item 2.02, Results of Operations and Financial Condition. These filings typically reference accompanying press releases that summarize revenue trends, research and development spending and updates across the company’s portfolio, including CFTR modulators such as ALYFTREK and TRIKAFTA, CASGEVY gene-edited cell therapy and JOURNAVX for acute pain. Other 8-K items may address changes in key executives or other corporate developments when they occur.
On Stock Titan, Vertex filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the main points of lengthy documents, so users can quickly understand how new information may relate to VRTX stock without reading every page. For example, AI summaries can highlight key themes in earnings-related 8-Ks, note significant changes in guidance or spending, and point out disclosures related to the progress of pivotal trials or regulatory submissions.
In addition to 8-Ks, users can review Vertex’s annual and quarterly reports when available, as well as any proxy materials and registration statements that may be filed. AI analysis tools on Stock Titan can surface trends across multiple filings, making it easier to track how Vertex’s financial profile and pipeline narrative evolve over time. This page is a useful starting point for anyone researching VRTX from a regulatory and disclosure perspective, complementing price charts, news and other fundamental data.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported a mix of stock sales, awards, and tax-related share disposals. On February 18, he completed an open‑market sale of 817 shares of common stock at an average price of $473.68 per share, leaving him with 20,727 directly owned shares after that sale.
On February 17, he received a grant of 4,962 shares of common stock at no cost, described as a restricted stock unit award that will vest in installments beginning on February 20, 2027. That same day, 2,031 shares were sold in open‑market transactions at an average price of $489.46 per share, and 1,530 shares were disposed of to cover tax obligations at a price of $483.75 per share. The open‑market sales were executed under a company‑approved Rule 10b5‑1 trading plan entered into on August 11, 2025.
Vertex Pharmaceuticals executive Kristen Ambrose reported several stock transactions involving company common shares. She received a grant of 1,809 shares as a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 598 shares were disposed of to cover tax obligations at a price of $483.75 per share, and 1,557 shares were sold in open-market transactions at $489.46 per share. On the following day, she sold an additional 638 shares at $473.68 per share under a company-approved Rule 10b5-1 trading plan that was entered into on August 8, 2025, leaving her with 7,750 directly owned shares after these transactions.
Vertex Pharmaceuticals executive Charles F. Wagner Jr. reported a tax-related share disposal. On February 13, 2026, he transferred 4,565 shares of common stock at $487.76 per share as a tax-withholding disposition, meaning shares were surrendered to cover taxes rather than sold on the open market. After this transaction, he directly owned 43,715 Vertex shares.
Vertex Pharmaceuticals executive Ourania Tatsis reported two stock transactions involving company common shares. On February 13, 2026, she disposed of 3,804 shares in a tax-withholding transaction at $487.76 per share and completed an open-market sale of 1,500 shares at a weighted average price of $499.99 per share.
The open-market sale was made under a company-approved Rule 10b5-1 trading plan entered into on August 21, 2025. Following these transactions, she directly owned 46,132 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev, EVP Chief Patient & External Affairs Officer, disposed of 3,548 shares of common stock on February 13, 2026 at $487.76 per share in a tax-withholding disposition. After this, he directly held 65,393 shares, with additional indirect holdings of 9,301 shares in a trust and 882 shares in a 401(k).
Vertex Pharmaceuticals executive Duncan McKechnie reported a tax-related share disposition. On this Form 4, he disposed of 2,283 shares of Vertex common stock on February 13, 2026 at an indicated price of $487.76 per share to cover tax obligations. After this transaction, he directly owned 19,528 shares.
Vertex Pharmaceuticals CEO Reshma Kewalramani reported a Form 4 tax-withholding disposition of 13,041 shares of common stock at $487.76 per share. After this transaction, she directly owns 133,487 Vertex shares.
Vertex Pharmaceuticals executive Mark E. Bunnage reported a tax-related share disposition. On this Form 4, he disposed of 2,283 shares of common stock at a price of $487.76 per share in a transaction coded "F," which represents payment of a tax liability by delivering shares, not an open-market sale. After this transaction, he directly owns 10,631 shares of Vertex common stock.
Vertex Pharmaceuticals executive reports tax-withholding share disposition. EVP and CMO Carmen Bozic disposed of 3,804 shares of Vertex Pharmaceuticals common stock on a tax-withholding basis at $487.76 per share. After this tax-withholding disposition, she directly holds 38,053 shares of Vertex common stock.
Vertex Pharmaceuticals executive Jonathan Biller reported two stock transactions. On February 13, 2026, he disposed of 2,993 shares of common stock at $487.76 per share to cover tax obligations and sold 988 shares in an open-market trade at $499.00 per share. After these transactions, he directly owned 16,838 shares of Vertex common stock. The filing notes the sale was made under a company-approved Rule 10b5-1 trading plan entered into on February 24, 2025.